DrugPatentWatch Database Preview
Ariad Company Profile
What is the competitive landscape for ARIAD, and what generic alternatives to ARIAD drugs are available?
ARIAD has two approved drugs.
There are six US patents protecting ARIAD drugs.
Summary for Ariad
| US Patents: | 6 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
| Patent Litigation for Ariad: | See patent lawsuits for Ariad |
Drugs and US Patents for Ariad
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ariad | ICLUSIG | ponatinib hydrochloride | TABLET;ORAL | 203469-001 | Dec 14, 2012 | RX | Yes | No | 9,029,533 | ➤ Sign Up | ➤ Sign Up | ||||
| Ariad | ICLUSIG | ponatinib hydrochloride | TABLET;ORAL | 203469-002 | Dec 14, 2012 | RX | Yes | Yes | 9,493,470 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Ariad | ALUNBRIG | brigatinib | TABLET;ORAL | 208772-001 | Apr 28, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | |||||
| Ariad | ICLUSIG | ponatinib hydrochloride | TABLET;ORAL | 203469-002 | Dec 14, 2012 | RX | Yes | Yes | 8,114,874 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Non-Orange Book US Patents for Ariad
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,278,307 | Monocyclic Heteroaryl compounds | ➤ Sign Up |
| 9,090,561 | Acetylenic heteroaryl compounds | ➤ Sign Up |
| 8,778,942 | Substituted acetylenic imidazo[1,2-A]pyrazine compounds as kinase inhibitors | ➤ Sign Up |
| 8,470,851 | Substituted acetylenic imidazo[1,2-A]pyridine compounds as kinase inhibitors | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Ariad Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Japan | 2017186345 | ➤ Sign Up |
| Slovenia | 1973545 | ➤ Sign Up |
| Hong Kong | 1158497 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 2014093583 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Ariad Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 327 | Luxembourg | ➤ Sign Up | PRODUCT NAME: PONATINIB SOUS TOUTES SES FORMES TELLES QUE PROTEGEES PAR LE BREVET DE BASE |
| 0 | Finland | ➤ Sign Up | |
| 13/059 | Ireland | ➤ Sign Up | PRODUCT NAME: PONATINIB IN ALL FORMS PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/839/001-004 20130701 |
| 1973545/01 | Switzerland | ➤ Sign Up | PRODUCT NAME: PONATINIBUM; REGISTRATION NO/DATE: SWISSMEDIC 63097 12.02.2014 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.
